CG Oncology Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Arthur Kuan
- Full Time Employees
- 142
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3000 Pegasus Park Drive Dallas TX United States of America 75247
- IPO Date
- Jan 25, 2024
- CIK
- 0001991792
- Website
- cgoncology.com
- Similar Companies
- Business
- CG Oncology, Inc. CG Oncology, Inc. (NASDAQ: CGON) is a late-stage clinical biopharmaceutical company that develops and seeks to commercialize oncolytic immunotherapies for bladder cancer patients; its lead product candidate, cretostimogene grenadenorepvec (cretostimogene), is an investigational intravesically delivered oncolytic immunotherapy evaluated in Phase 3 trials including BOND-003 for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without Ta/T1 disease, PIVOT-006 for intermediate-risk NMIBC, and Phase 2 CORE-001, CORE-002, and CORE-008 trials assessing cretostimogene as monotherapy or in combination with pembrolizumab, nivolumab, or gemcitabine across high-risk BCG-unresponsive, BCG-naïve, and BCG-exposed NMIBC patient populations. Founded in 2010 and headquartered in Irvine, California, with additional offices in Emeryville, California, and Branchburg, New Jersey, the company targets urologic cancers, particularly NMIBC, where it aims to provide bladder-sparing alternatives to cystectomy for patients facing BCG failure or limited treatment options. CG Oncology operates an Expanded Access Program for cretostimogene in North America for BCG-unresponsive patients meeting eligibility criteria. In recent developments, CG Oncology initiated a rolling Biologics License Application (BLA) submission to the U.S. FDA in third-quarter 2025 for cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease, supported by Fast Track and Breakthrough Therapy Designations, with full submission expected in 2026. The company reported best-in-disease 24-month complete response rates of 41.8% to 42.3% in BOND-003 Cohort C, with 90% of 12-month responders remaining disease-free and no Grade 3 or higher treatment-related adverse events. Enrollment completed ahead of schedule in the PIVOT-006 Phase 3 trial in September 2025, and topline data from BOND-003 Cohort P and CORE-008 Cohort A are anticipated in fourth-quarter 2025; additionally, the company completed an oversubscribed $238 million follow-on public equity offering in 2024 and raised further proceeds via its at-the-market facility in 2025, extending its cash runway into first-half 2028.
Company News
15 Stocks to Watch With Short Squeeze Potential
CG Oncology to Present at Upcoming Investor Conferences in September
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
CG Oncology: Circling Back After Huge Rally
CG Oncology, Inc. $CGON Shares Bought by California State Teachers Retirement System
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
CG Oncology to Present at Upcoming Investor Conferences in June
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC